← Back to Clinical Trials
Recruiting NCT05942924

NCT05942924 The NEU-STIM Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05942924
Status Recruiting
Phase
Sponsor Leiden University Medical Center
Condition Infant, Premature, Diseases
Study Type INTERVENTIONAL
Enrollment 3,280 participants
Start Date 2024-03-11
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 32 Weeks
Study Type INTERVENTIONAL
Interventions
Repeated tactile stimulationSelective tactile stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 3,280 participants in total. It began in 2024-03-11 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to determine the effect of repetitive tactile stimulation compared to selective stimulation on oxygenation of the infant at 5 minutes after birth. Infants born before 32 weeks of gestation will be included in this trial. This is a stepped-wedge cluster randomised controlled trial. The participating centre, rather than the individual infant, will be the unit of randomisation. This design is appropriate to test the effect of an intervention that encompasses a behavioral aspect - in this case the performance of tactile stimulation.

Eligibility Criteria

Inclusion Criteria: * Infants born before 32 weeks of gestation can be included in this trial after parental consent. Exclusion Criteria: * Infants will be excluded if they are found to have a congenital abnormality or condition that has an adverse effect on breathing/ventilation or oxygenation, including: congenital diaphragmatic hernia, trachea-oesophageal fistula, cyanotic heart disease and surfactant protein deficiency. Many of the infants enrolled in the study will later be diagnosed with respiratory distress syndrome (RDS); this will not render them ineligible for inclusion.

Contact & Investigator

Central Contact

Janneke Dekker, PhD

✉ j.dekker@lumc.nl

📞 +31715266620

Frequently Asked Questions

Who can join the NCT05942924 clinical trial?

This trial is open to participants of all sexes, up to 32 Weeks, studying Infant, Premature, Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05942924 currently recruiting?

Yes, NCT05942924 is actively recruiting participants. Contact the research team at j.dekker@lumc.nl for enrollment information.

Where is the NCT05942924 trial being conducted?

This trial is being conducted at Graz, Austria, Liège, Belgium, Rijeka, Croatia, Split, Croatia and 11 additional locations.

Who is sponsoring the NCT05942924 clinical trial?

NCT05942924 is sponsored by Leiden University Medical Center. The trial plans to enroll 3,280 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology